Lasa Supergenerics Ltd.
Snapshot View

71.80 -1.90 ▼-2.6%

05 August 2021, 04:00:00 P.M.
Volume: 33,487

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lasalabs.com
Financial Indicators
Market Cap 293.25 Cr.
Earnings per share (EPS) 5.60 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 12.87 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 39.07 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.85 Calculated using Price: 72.10
Dividend Yield 0.35 Period Ending 2020-03
No. of Shares Subscribed 4.07 Cr. 40,672,668 Shares
FaceValue 10
Company Profile

Lasa Supergenerics (Lasa) is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012. The manufacturing base of Lasa group is located at Mahad, in the Konkan region of Maharashtra. It specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India. To efficiently control the supply chain, the group backward integrated its key molecules-from discovery research up to full-scale bulk production.

Lasa group’s marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The group has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations.

Business area of the company

The company is specialises in ‘catalyst chemistry’ and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India

Product Categories

  • Veterinary API Products
  • Other API Products
  • Animal Feed Ingredients
  • Reagents For Therapeutic Use


Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.58%
1 Week
-3.43%
1 Month
-12.97%
3 Month
-7.12%
6 Month
-9.86%
1 Year
+22.95%
2 Year
+620.16%
5 Year
5 years 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 8.65 14.33 -10.81 2.94
Return on Capital Employed (%) 14.45 12.80 -3.73 6.77
Return on Assets (%) 2.07 4.79 -4.44 1.50

Balance Sheet View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 0 75 117 105 141
Non Curr. Liab. 0 83 62 43 11
Curr. Liab. 70 107 107 76
Minority Int.
Equity & Liab. 0 228 287 255 229
Non Curr. Assets 149 178 170 153
Curr. Assets 0 79 109 86 76
Misc. Exp. not W/O 0
Total Assets 0 228 287 255 229

Profit Loss View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 199 244 170 167
Other Income 2 3 1 0
Total Income 201 247 170 167
Total Expenditure -153 -202 -159 -137
PBIDT 48 45 12 30
Interest -12 -11 -8 -8
Depreciation -8 -18 -19 -17
Taxation 0 -3 4 -1
Exceptional Items -26
PAT 2 12 -12 4

Cash Flow View Details

Particulars 5 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 -3 40 41 14
Cash Fr. Inv. 0 -44 -7 -2
Cash Fr. Finan. 0 0 4 -33 -10
Net Change 0 -3 0 0 2
Cash & Cash Eqvt 0 0 1 0 3

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 34.59 63.24 36.80 64.47 64.47 64.47 64.47 64.47 64.47
Public 65.41 36.76 63.20 35.53 35.53 35.53 35.53 35.53 35.53
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 100.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 05 Aug 2021
Certificate Of Non-Disqualification Of Directors Under Regulation 34(3) Of SEBI(Listing Obligations And Disclosure Requirements) Regulations 2015 For The Financial<BR> Year Ended March 31 2021.
In pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Certificate of Non Disqualification of Directors for the Financial Year Ended on 31 March 2021 issued by M/s. Shivam Sharma & Associates. Practicing Company Secretaries Secretarial Auditors of the Company dated August 04 2021.
Mon, 26 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Attached is a copy of Press Release tilted No Casualty in any of companys units. Production to recommence in couple of Weeks. Issued by the company.
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbances
Pursuant to the Regulation 30 read with Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and the Circular Ref no. CIWCFDICMD/4/2015 dated September 09 2015 issued by SEBI we wish to inform you that fire accident occurred today in our Plant situated at Mahad Dist raigad and also heavy rains in the Konkan region has disrupted all operations in all Units situated at Chiplun. The rains which lashed the city led to water logging and inflow of water into factory premises resulting in some damage to inventory and Machineries.

Technical Scans View Details

Wed, 04 Aug 2021
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,075.50 +0.2%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%